Intercept Pharmaceuticals Valuation

Intercept Pharmaceuticals Investor Information

About 81.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 4.26. Intercept Pharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to Intercept Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Intercept Pharmaceuticals is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.

Intercept Pharmaceuticals Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Intercept Pharmaceuticals has an asset utilization ratio of 51.6 percent. This implies that the Company is making $0.52 for each dollar of assets. An increasing asset utilization means that Intercept Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.

Intercept Pharmaceuticals Ownership Allocation

Intercept Pharmaceuticals has a total of 41.81 Million outstanding shares. The majority of Intercept Pharmaceuticals outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Intercept Pharmaceuticals to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Intercept Pharmaceuticals. Please pay attention to any change in the institutional holdings of Intercept Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Intercept Pharmaceuticals Profitability Analysis

The company reported the previous year's revenue of 285.71 M. Net Loss for the year was (174.86 M) with profit before overhead, payroll, taxes, and interest of 284.73 M.

Investing in growth stocks can be very risky. If the company such as Intercept Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

If you are still planning to invest in Intercept Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intercept Pharmaceuticals' history and understand the potential risks before investing.